Drossapharm AG is a OTC and phyto company based in Basel (Basel-Stadt) recorded by Swissmedic as the authorisation holder for 62 human medicines. That places it 23 of 334 authorisation holders in Switzerland. Its portfolio is concentrated in Synthetika.
Key facts
| Sector | OTC and phyto |
|---|---|
| City | Basel |
| Canton | Basel-Stadt |
| Authorisation holder | Yes |
| Medicines | 62 |
| Founded | Not available |
| Employees | 11-50 |
| Parent group | Not available |
| Activity | Not available |
| Website | drossapharm.ch |
Medicines authorised in Switzerland
Drossapharm AG is recorded by Swissmedic as the authorisation holder for 62 human medicines. The table shows 48 of them with product code and dispensing category.
Portfolio by product code
Portfolio by dispensing category
48 of 62 authorisations
| Name | Authorisation number | Dispensing category | ATC | First authorised |
|---|---|---|---|---|
| Acemetax | 57828 | B | - | 2007-04-20 |
| Acemetax retard | 57829 | B | - | 2007-04-20 |
| Aknilox 2% | 51303 | B | D10AF02 | 1993-01-11 |
| Apixax 2.5 mg | 70406 | B | B01AF02 | 2026-05-26 |
| Atorvastax 10 mg | 62613 | B | C10AA05 | 2012-02-20 |
| Cardiax ASS 100 | 55197 | B | B01AC06 | 1999-11-05 |
| Clopidrax | 61340 | B | B01AC04 | 2010-10-01 |
| Drossadin 0.1 % | 39798 | D | A01AB12 | 1976-07-30 |
| Drossadin Spray 0.2% | 65701 | D | A01AB12 | 2016-07-13 |
| Drossafol | 56272 | B | B03BB01 | 2003-05-07 |
| Escitax 10 mg | 66357 | B | N06AB10 | 2017-08-31 |
| Esoprax 20 mg | 66321 | B | A02BC05 | 2017-07-12 |
| Finasterax | 58039 | B | G04CB01 | 2007-10-17 |
| Fluconax 50 mg | 57182 | B | J02AC01 | 2005-01-13 |
| Gorgonium | 46626 | D | C05BA53 | 1989-05-17 |
| Keppur | 43996 | D | M02AX10 | 1981-07-02 |
| Keppur | 47122 | D | M02AX10 | 1985-12-19 |
| Liquemin 20'000 I.E. / 48 ml | 70519 | B | B01AB01 | 2026-05-28 |
| Liquemin 25'000 I.E. / 5 ml | 15159 | B | B01AB01 | 1949-06-14 |
| Lixim Patch | 67494 | D | M02AA06 | 2020-07-22 |
| Lur | 57475 | B | D01AC08 | 2005-06-07 |
| Luvit D3 zur Prophylaxe | 66124 | B/D | A11CC05 | 2016-04-14 |
| Lyman 200'000 forte | 52855 | D | C05BA53 | 1996-06-26 |
| Lyman 40'000 Mono | 55744 | D | C05BA03 | 2002-06-25 |
| Lyman 50'000 | 52854 | D | C05BA53 | 1996-06-26 |
| Lyman-200'000 forte | 43511 | D | C05BA53 | 1981-01-07 |
| Lyman-200'000 forte | 45564 | D | C05BA53 | 1984-04-02 |
| Lyman-50'000 | 41560 | D | C05BA53 | 1978-12-15 |
| Lyman-50'000 | 45563 | D | C05BA53 | 1984-04-02 |
| Mediaven 10 mg | 37979 | B | C05CX02 | 1973-06-21 |
| Minocin Akne 50 mg | 45465 | A | J01AA08 | 1984-12-10 |
| Oestro-Gynaedron | 52195 | B | G03CA04 | 1995-09-26 |
| Olanpax 10 mg | 62224 | B | N05AH03 | 2011-09-09 |
| Olanpax 2.5 mg | 62223 | B | N05AH03 | 2011-09-09 |
| Omeprax-Drossapharm 10mg | 65979 | B | A02BC01 | 2015-11-04 |
| Panprax 20 mg | 60408 | B | A02BC02 | 2010-04-29 |
| Perilox | 50483 | B | D06BX01 | 1990-10-30 |
| Rheumalix | 42203 | D | M02AA06 | 1979-07-30 |
| Rheumalix forte | 55515 | D | M02AA06 | 2000-09-04 |
| Rheumalix forte | 58017 | D | M02AA06 | 2007-10-05 |
| Rivarax 10 mg | 69032 | B | B01AF01 | 2024-01-29 |
| Roaccutan | 52685 | B | D10AD04 | 1994-08-18 |
| Rosalox | 48092 | B | D06BX01 | 1987-03-13 |
| Rosuvastax 5 mg | 66447 | B | C10AA07 | 2017-06-28 |
| Rosuvastax-Drossapharm 5 mg | 69613 | B | C10AA07 | 2025-04-03 |
| Sebolox | 57686 | B | D01AC02 | 2008-05-13 |
| Siccalix | 47880 | D | R01AX10 | 1987-10-09 |
| Sildenax 25 mg | 60179 | B | G04BE03 | 2011-01-21 |
Frequently asked questions
How many medicines does Drossapharm AG have authorised in Switzerland?
Drossapharm AG is recorded by Swissmedic as the authorisation holder for 62 human medicines (as of 1 September 2026). Different strengths under one authorisation number are not counted separately.
Where is Drossapharm AG based?
The Swiss location recorded for Drossapharm AG is Basel, Basel-Stadt.
Is Drossapharm AG a Swissmedic authorisation holder?
Yes. Drossapharm AG appears in the official Swissmedic list of authorised medicinal products as an authorisation holder. Under the Therapeutic Products Act (TPA) the holder is responsible for the quality, safety and product information of its medicines in Switzerland.